F-1: PomDoctor Files for U.S. IPO, Aiming to List on Nasdaq

PomDoctor Limited, a Cayman Islands-based holding company operating primarily in China, has filed for an initial public offering (IPO) in the U.S., seeking to list its American Depositary Shares (ADSs) on the Nasdaq Stock Market.

Summary

• PomDoctor Limited, a Cayman Islands holding company with operations mainly in China, has filed an F-1 registration statement for an IPO of its American Depositary Shares (ADSs).
• The company operates an online medical services platform focused on chronic disease management and pharmaceutical services.
• PomDoctor's operations are primarily conducted through a Variable Interest Entity (VIE), Guangzhou Qilekang Digital Health Medical Technology Co., Ltd., and its subsidiaries in China.
• The company plans to list its ADSs on the Nasdaq Stock Market under the ticker symbol 'POM'.
• The initial public offering price is expected to be between US$ and US$ per ADS.
• The company intends to use the net proceeds from the offering for supply chain stocking, expansion of departmental and geographic coverage, research and development, working capital and general corporate purposes.
• The digital healthcare market in China is projected to grow from RMB540.7 billion in 2022 to RMB1,525.9 billion in 2027, representing a CAGR of approximately 23.1%.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company operates in a growing market and has some positive operational metrics, the going concern warning and reliance on a VIE structure introduce significant risks. The sentiment is neutral, reflecting both opportunities and challenges.

Positives

• High retention rate for mature doctors (99.9% in the six months ended June 30, 2024) indicates doctor satisfaction and platform stability.
• Strong patient repurchase rate (65.5% in the six months ended June 30, 2024) suggests user loyalty and effective chronic disease management.
• Growing digital healthcare market in China presents significant opportunities for expansion.
• Experienced management team and well-renowned shareholders provide validation and support.
• The company has completed the required filings with the CSRC for this offering, and the CSRC has concluded the filing procedure and published the filing results on the CSRC website on January 17, 2025.

Negatives

• The report of the company's independent registered public accounting firm includes an explanatory paragraph that expresses substantial doubt about the company's ability to continue as a going concern.
• The company has incurred operating losses in the past, expects to incur operating losses in the future, and may not be able to achieve or maintain profitability.
• The company faces risks of medical liability claims against its contracted doctors on the platform and the company in connection with its online healthcare services.
• The company may be subject to penalties or disputes against it for failure to manage its doctors on its platform.

Risks

• Reliance on a VIE structure introduces regulatory and enforcement risks related to PRC laws.
• The company faces legal and operational risks associated with operating primarily in China, including regulatory approvals and cybersecurity concerns.
• The company's business is subject to evolving PRC laws and regulations, which may change quickly and impact operations.
• The company may face difficulties in attracting or retaining sufficient users or medical professionals for its online healthcare services.
• The company may not be able to develop its existing information infrastructure and technologies or recoup the investments it has made for such development.
• The company may be subject to penalties or disputes against it for failure to manage its doctors on its platform.
• The company may be subject to penalties or disputes against it for failure to manage its doctors on its platform.
• The company may be subject to penalties or disputes against it for failure to manage its doctors on its platform.

Future Outlook

The company expects its operating expenses to increase in the future as it expands its operations. The company plans to use the net proceeds from the offering for supply chain stocking, expansion of departmental and geographic coverage, research and development, working capital and general corporate purposes.

Management Comments

• Our mission is to provide effective prevention and treatment solutions to alleviate patients sufferings from illnesses.
• Our vision is to become the most trustworthy medical and healthcare services platform.

Industry Context

The digital healthcare market in China is experiencing rapid growth, driven by factors such as an aging population, rising prevalence of chronic diseases, and increasing health awareness. The market size is projected to reach RMB1,525.9 billion in 2027, representing a CAGR of approximately 23.1% from 2022.

Comparison to Industry Standards

• PomDoctor ranks sixth in China's Internet hospital market based on the number of contracted doctors in 2022, according to Frost & Sullivan.
• The company's average revenue per paying patient on the platform of RMB714 in 2023, which increased as compared with RMB624 in 2022.
• The company's repeat purchase rate of patients in its hepatopathy department was 73.1% and 72.7% in 2022 and 2023, respectively.
• The company's 90-day patient repurchase rate, representing the average turnover period of the prescription drug usage, of 65.9%, 63.7% and 65.5% in 2022, 2023 and the six months ended June 30, 2024, respectively.
• The average inventory turnover days of the top 5 offline pharmacies in China in 2022 were 87.8 days, compared with 26.3 days in the United States.

Related Party Transactions

• The company has engaged in various related party transactions, including loans from its CEO, his spouse, and other related entities.
• The company has entered into an Exclusive Business Cooperation Agreement with its VIE.
• The company has entered into employment agreements and indemnification agreements with its executive officers.

Stakeholder Impact

• Shareholders: Potential for growth in a developing market, but also significant risks related to the VIE structure and regulatory environment.
• Employees: Opportunities for growth and development within the company, but also potential job insecurity due to the company's financial situation.
• Customers: Access to convenient online medical services, but also potential risks related to data privacy and service quality.
• Suppliers: Opportunities for increased sales through the company's platform, but also potential risks related to payment and contract terms.

Next Steps

• The company will continue to recruit quality doctors onto its platform and attract more patient users.
• The company will continue to expand and strengthen its presence in key cities and provinces across China.
• The company will continue to enhance its supply chain capabilities.
• The company will continue to invest in research and development and enhance its technology capabilities.
• The company will explore new patient acquisition channels via enhanced B2B collaboration.
• The company will utilize its accumulated big data to empower the industry.
• The company will expand its experience and reputation in chronic diseases to more medical areas.

Key Dates

Keywords

IPO, digital healthcare, chronic disease management, online medical services, pharmaceutical supply chain, China, Nasdaq, ADS, VIE